Novartis: enters into NASH development deal with Pfizer
(CercleFinance.com) - Novartis said that it has entered into a clinical development agreement with US giant Pfizer to advance the treatment of non-alcoholic steatohepatitis (NASH).
The agreement includes a clinical trial to evaluate a combination of Novartis' tropifexor with one or more Pfizer compounds for the treatment of this complex liver disease that has no treatment options.
NASH - which is estimated to affect up to 6.5% of the population worldwide - is largely asymptomatic, even though fat builds up in the liver, triggering chronic inflammation.
Over time, fibrosis may progress to cirrhosis, which can lead to liver failure and death.
The financial details of the deal have not been disclosed.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The agreement includes a clinical trial to evaluate a combination of Novartis' tropifexor with one or more Pfizer compounds for the treatment of this complex liver disease that has no treatment options.
NASH - which is estimated to affect up to 6.5% of the population worldwide - is largely asymptomatic, even though fat builds up in the liver, triggering chronic inflammation.
Over time, fibrosis may progress to cirrhosis, which can lead to liver failure and death.
The financial details of the deal have not been disclosed.
Copyright (c) 2018 CercleFinance.com. All rights reserved.